Skip to main content
SpringerLink
Log in

SNRIs vs SSRIs: no increased risk of antihypertensive treatment intensification or MACE

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression Pharmacotherapy : 9 May 2022. Available from: URL: http://doi.org/10.1002/phar.2686

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SNRIs vs SSRIs: no increased risk of antihypertensive treatment intensification or MACE. Reactions Weekly 1906, 12 (2022). https://doi.org/10.1007/s40278-022-14902-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-14902-9

Search

Navigation